The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension

Diabetes Research and Clinical Practice

Volumn 74, Issue 3, 2006, Pages 242-248

  Saiki, Atsuhito ^a   Ohira, Masahiro ^a   Endo, Kei ^a   Koide, Nobukiyo ^a   Oyama, Tomokazu ^a   Murano, Takeyoshi ^b   Miyashita, Yoh ^a   Shirai, Kohji ^c  

^a National Hospital Organization   (Japan)

^b Sakura Hospital   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipocyte; Angiotensin II; LDL particle size; Preheparin serum lipoprotein lipase mass; Valsartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VALSARTAN;

ADIPOCYTE; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC HYPERTENSION; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 33750032953     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.04.004     Document Type: Article

References (43)

1. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
2. Yusuf S., et al. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
3. Dahlof B., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
4. Julius S., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
5. Hanefeld M., and Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J. Int. Med. Res. 29 (2001) 270-279
6. Cheung R., Lewanczuk R.Z., Rodger N.W., Huff M.W., Oddou-Stock P., Botteri F., et al. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int. J. Clin. Pract. 53 (1999) 584-592
7. Miyashita Y., Ito Y., Hasiguchi S., Totsuka M., Aoki A., Kurokawa M., et al. Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus. J. Atheroscler. Thromb. 81 (2001) 25-29
8. Ailhaud G., Fukamizu A., Massiera F., Negrel R., Saint-Marc P., and Teboul M. Angiotensinogen, angiotensin II and adipose tissue development. Int. J. Obes. Relat. Metab. Disord. 4 (2000) 33-35
9. Janke J., Engeli S., Gorzelniak K., Luft F.C., and Sharma A.M. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51 (2002) 1699-1707
10. Engeli S., Negrel R., and Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35 (2000) 1207-1270
11. Schling P., Mallow H., Trindl A., and Loffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int. J. Obes. Relat. Metab. Disord. 23 (1999) 336-341
12. Engeli S., Gorzelniak K., Kreutz R., Runkel N., Distler A., and Sharma A.M. Co-expression of renin-angiotensin system genes in human adipose tissue. J. Hypertens. 17 (1999) 555-560
13. Braun J.E.A., and Severson D.L. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochemistry 287 (1992) 337-347
14. Sexena U., Klein M.G., and Goldberg I.J. Transport of lipoprotein lipase across endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2254-2258
15. Sexena U., Wit L.A.D., and Goldberg I.J. Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acid. J. Biol. Chem. 264 (1982) 4349-4355
16. Peterson J., Bihain B.E., Bengtsson-Olivecrona G., Deckelbaum D.J., Carpentier Y.A., and Olivecrona T. Fatty acid control of lipoprotein lipase, a link between energy metabolism and lipid transport. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 909-913
17. Kobayashi J., Hashimoto H., Fukamachi I., Tashiro J., Shirai K., Saito Y., et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin. Chem. Acta 216 (1993) 113-123
18. Tornvall P., Olivecrona G., Karpe F., Andres H., and Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1086-1093
19. Watanabe H., Miyashita Y., Murano T., Hiroh Y., Itoh Y., and Shirai K. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 145 (1999) 45-50
20. Miyashita Y., Shirai K., Itoh Y., Sasaki H., Totsuka M., Murano T., et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res. Clin. Pract. 56 (2002) 181-187
21. Totsuka M., Miyashita Y., Ito Y., Watanabe H., Murano T., and Shirai K. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis 153 (2000) 175-179
22. Nilsson-Ehle P.A., Garfinkel A.S., and Schotz M.C. Lipolytic enzymes and plasma lipoprotein metabolism. Annu. Rev. Biochem. 49 (1980) 667-693
23. Louis C.S., and Henry J.P. Lipoprotein lipase, lipases (1984), Elsevier, Amsterdam pp. 263-305
24. Shirai K., Itoh Y., Sasaki H., Totsuka M., Murano T., Watanabe H., et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res. Clin. Pract. 46 (1999) 35-41
25. The Committee of Japan Diabetes Society for the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee of Japan Diabetes Society on the Classification and Diagnostic Criteria of Diabetes Mellitus, J. Jpn. Diabetes Soc. 42 (1999) 385-404.
26. Kobayashi J., Hashimoto H., Fukamachi I., Tashiro J., Shirai K., Saito Y., et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin. Chem. Acta 216 (1993) 113-123
27. Feingold K.R., Grunfeld C., Pang M., Doerrler W., and Krauss R.M. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler. Thromb. 12 (1992) 1496-1502
28. Shirai K., Nema T., Hiroh Y., Itoh Y., Miyashita Y., and Watanabe H. Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterol. J. Clin. Lab. Anal. 112 (1997) 82-86
29. Burstein M., Scholnick H.R., and Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid. Res. 11 (1970) 583-595
30. Mishima Y., Ando M., Kuyama A., and Kibata Y. A simple method for identifying particle size of low-density lipoprotein using PAG™ electrophoresis; Comparison between LipoPhor™ and LipoPrint LDL™ systems. J. Jpn. Atheroscler. Soc. 25 (1997) 67-70
31. Totsuka M., Miyashita Y., Ito Y., Watanabe J., and Shirai K. Properties of fast 13 lipoprotein on the PAG disc electrophoresis and its role in diabetic complications. J. Jpn. Diabetes Soc. 40 (1997) 503-511
32. Shirai K. Evaluation of obesity and diagnostic criteria of obesity as a disease for Japanese. Nippon Rinsho 59 (2001) 578-585
33. Folli F., Saad M.J., Velloso L., Hansen H., Carandente O., Feener E.P., et al. Crosstalk between insulin and angiotensin II signalling systems. Exp. Clin. Endocrinol. Diabetes 107 (1999) 133-139
34. Ong J.M., Kirchgessner T.G., Schotz M.C., and Kern P.A. Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes. J. Biol. Chem. 263 (1988) 12933-12938
35. Semenkovich C.F., Wims M., Noe L., Etienne J., and Chan L. Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at posttranscriptional and posttranslational levels. J. Biol. Chem. 264 (1989) 9030-9038
36. Kobayashi J., Saito K., Fukamachi I., Taira K., Takahashi K., Bujyo H., et al. Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation. Horm. Metab. Res. 33 (2001) 412-416
37. Hanyu O., Miida T., Obayashi K., Ikarashi T., Soda S., Kaneko S., et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174 (2004) 385-390
38. Austin M.A., King M.C., Vranizan K.M., and Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
39. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., and Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
40. Tamasawa N., Matsui J., Ogawa Y., Gotoh T., Hinata T., Murakami H., et al. Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension. J. Diabetes Complications 14 (2000) 135-139
41. Pfeffer M.A., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
42. Hitsumoto T., Ohsawa H., Uchi T., Noike H., Kanai M., Yoshinuma M., et al. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 153 (2000) 391-396
43. Hitsumoto T., Yoshinaga K., Aoyagi K., Sakurai T., Kanai M., Uchi T., et al. Association between preheparin serum lipoprotein lipase mass and acute myocardial infarction in Japanese men. J. Atheroscler. Thromb. 9 (2002) 163-169